Bio-Rad Laboratories, Inc. (BIO.B)
NYSE: BIO.B · Real-Time Price · USD
334.85
0.00 (0.00%)
Nov 1, 2024, 8:30 AM EST - Market closed
Bio-Rad Laboratories Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for BIO.B stock have an average target of 411, with a low estimate of 340 and a high estimate of 469. The average target predicts an increase of 22.74% from the current stock price of 334.85.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for BIO.B stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 2 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $400 → $450 | Strong Buy | Maintains | $400 → $450 | +34.39% | Oct 31, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $446 → $469 | Buy | Maintains | $446 → $469 | +40.06% | Oct 31, 2024 |
| Citigroup | Citigroup | Hold → Strong Buy Upgrades $350 → $400 | Hold → Strong Buy | Upgrades | $350 → $400 | +19.46% | Oct 1, 2024 |
| Wells Fargo | Wells Fargo | Hold Initiates $340 | Hold | Initiates | $340 | +1.54% | Aug 27, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $401 | Buy | Reiterates | $401 | +19.76% | Aug 16, 2024 |
Financial Forecast
Revenue This Year
2.60B
from 2.67B
Decreased by -2.63%
Revenue Next Year
2.72B
from 2.60B
Increased by 4.42%
EPS This Year
9.47
from -21.82
EPS Next Year
11.12
from 9.47
Increased by 17.42%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 2.7B | 2.9B | 3.0B | ||
| Avg | 2.6B | 2.7B | 2.8B | ||
| Low | 2.5B | 2.6B | 2.7B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 1.9% | 9.7% | 9.9% | ||
| Avg | -2.6% | 4.4% | 4.4% | ||
| Low | -6.0% | -0.0% | -0.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 10.79 | 12.30 | 13.76 | ||
| Avg | 9.47 | 11.12 | 12.47 | ||
| Low | 8.69 | 9.93 | 11.12 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 29.9% | 23.7% | ||
| Avg | - | 17.4% | 12.2% | ||
| Low | - | 4.9% | 0.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.